Significance of the minor cytochrome P450 3A isoforms

被引:190
作者
Daly, AK [1 ]
机构
[1] Newcastle Univ, Sch Med, Sch Clin & Lab Sci, Pharmacogenet Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
D O I
10.2165/00003088-200645010-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 (CYP) 3A4 is responsible for most CYP3A-mediated drug metabolism but the minor isoforms CYP3A5, CYP3A7 and CYP3A43 also contribute. CYP3A5 is the best studied of the minor CYP3A isciforms. It is well established that only approximately 20% of livers express CYP3A5. The most common reason for the absence of expression is a splice site mutation. The frequency of variant alleles shows interethnic differences, with the wild-type CYP3A5*1 allele more common in Africans than Caucasians and Asians. In individuals who express CYP3A5, the percentage contributed to total hepatic CYP3A by this isoform, is still unclear, with estimates ranging from 17% to 50%. CYP3A5 is also expressed in a range of extrahepatic tissues. Only limited information is available on the regulation of CYP3A5 expression but it appears to be inducible via the glucocorticoid receptor, pregnane X receptor and constitutive androstane receptor-P, as for CYP3A4. Although information on the substrate specificity of CYP3A5 is limited compared with CYP3A4, there have been a number of recent pharmacokinetic studies on a small range of substrates in individuals of known genotype to investigate the contribution of CYP3A5. In the case of midazolam, ciclosporin, nifedipine and docetaxel, clearance by individuals with a CYP3A5-expressing genotype did not differ from that for nonexpressors, but in the case of tacrolimus, eight independent studies have demonstrated faster clearance by those carrying one or two CYP3A5*1 alleles. This may reflect faster turnover of tacrolimus by CYP3A5 than the other substrates. CYP3A5 genotype may affect cancer susceptibility. Certain combined CYP3A4/CYP3A5 haplotypes show differential susceptibility to prostate cancer and there is a nonsignificant increase in the risk of small-cell lung cancer for a CYP3A5*1/*1 genotype. Females positive for CYP3A5*1 appear to reach puberty earlier, which may affect breast cancer risk. CYP3A5*1 homozygotes may have higher systolic blood pressure. CYP3A7 is predominantly expressed in fetal liver but is also found in some adult livers and extrahepatically. The molecular basis for expression in adult liver relates to upstream polymorphisms, which appear to increase homology to CYP3A4 and make regulation of expression more similar. CYP3A7 has a specific role in hydroxylation of retinoic acid and 16 alpha-hydroxylation of steroids, and is therefore of relevance both to normal development and carcinogenesis. CYP3A43 is the most recently discovered CYP3A isoform. In addition to a low level of expression in liver, it is expressed in prostate and testis. Its substrate specificity is currently unclear. Polymorphisms predicting absence of active enzyme have been identified.
引用
收藏
页码:13 / 31
页数:19
相关论文
共 121 条
[91]   Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1 alpha,25-dihydroxyvitamin D-3 [J].
SchmiedlinRen, P ;
Thummel, KE ;
Fisher, JM ;
Paine, MF ;
Lown, KS ;
Watkins, PB .
MOLECULAR PHARMACOLOGY, 1997, 51 (05) :741-754
[92]  
Schuetz JD, 1996, MOL PHARMACOL, V49, P63
[93]   SELECTIVE EXPRESSION OF CYTOCHROME-P450 CYP3A MESSENGER-RNAS IN EMBRYONIC AND ADULT HUMAN LIVER [J].
SCHUETZ, JD ;
BEACH, DL ;
GUZELIAN, PS .
PHARMACOGENETICS, 1994, 4 (01) :11-20
[94]   IDENTIFICATION OF THE FETAL LIVER CYTOCHROME-CYP3A7 IN HUMAN ENDOMETRIUM AND PLACENTA [J].
SCHUETZ, JD ;
KAUMA, S ;
GUZELIAN, PS .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (02) :1018-1024
[95]   CHARACTERIZATION OF A CDNA-ENCODING A NEW MEMBER OF THE GLUCOCORTICOID-RESPONSIVE CYTOCHROMES P450 IN HUMAN-LIVER [J].
SCHUETZ, JD ;
MOLOWA, DT ;
GUZELIAN, PS .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1989, 274 (02) :355-365
[96]   Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes [J].
Shih, PS ;
Huang, JD .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1491-1496
[97]  
Shimada T, 1996, DRUG METAB DISPOS, V24, P515
[98]   Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver [J].
Shou, MG ;
Martinet, M ;
Korzekwa, KR ;
Krausz, KW ;
Gonzalez, FJ ;
Gelboin, HV .
PHARMACOGENETICS, 1998, 8 (05) :391-401
[99]   CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele [J].
Sim, SC ;
Edwards, RJ ;
Boobis, AR ;
Ingelman-Sundberg, M .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) :625-631
[100]   The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer [J].
Spurdle, AB ;
Goodwin, B ;
Hodgson, E ;
Hopper, JL ;
Chen, XQ ;
Purdie, DM ;
McCredie, MRE ;
Giles, GG ;
Chenevix-Trench, G ;
Liddle, C .
PHARMACOGENETICS, 2002, 12 (05) :355-366